Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Vaccine ; 35(33): 4245-4254, 2017 07 24.
Article in English | MEDLINE | ID: mdl-28625523

ABSTRACT

Eczema vaccinatum is a severe and occasionally lethal complication of smallpox vaccine, characterized by systemic viral dissemination, distant from the initial inoculation site of the vaccine. A major risk factor for eczema vaccinatum is a background of atopic dermatitis, a chronic, common allergic, relapsing disorder, manifested by dry and inflamed skin, itchy rash, Th2 biased immune response and hypersensitivity to various antigens. Unlike the severe manifestations of eczema vaccinatum in humans, current models present only mild symptoms that limits examination of potential therapeutics for eczema vaccinatum. The atopic dermatitis and eczema vaccinatum models we present here, are the first to simulate the severity of the diseases in humans. Indeed, dermatitic mice display persistent severe dermatitis, characterized by dry and inflamed skin with barrier dysfunction, epidermal hyperplasia and significant elevation of serum IgE. By exposing atopic dermatitis mice to ectromelia virus, we generated eczema vaccinatum that mimic the human disease better than known eczema vaccinatum models. Similarly to humans, eczematous mice displayed enlarged and disseminated skin lesions, which correlated with elevated viral load. Cidofovir and antiviral antibodies conferred protection even when treatment started at a late eczematous stage. Moreover, we are the first to demonstrate that despite a severe background of atopic dermatitis, modified vaccinia Ankara virus (MVA) vaccination protects against lethal ectromelia virus exposure. We finally show that protection by MVA vaccination is dependent on CD4+ T cells and is associated with significant activation of CD8+ cytotoxic T cells and induction of humoral immunity.


Subject(s)
Dermatitis, Atopic/complications , Disease Models, Animal , Ectromelia virus/immunology , Kaposi Varicelliform Eruption/drug therapy , Kaposi Varicelliform Eruption/prevention & control , Smallpox Vaccine/administration & dosage , Smallpox Vaccine/adverse effects , Animals , Antibodies, Viral/administration & dosage , Antiviral Agents/administration & dosage , CD4-Positive T-Lymphocytes , Cidofovir , Cytosine/administration & dosage , Cytosine/analogs & derivatives , Ectromelia virus/pathogenicity , Female , Humans , Kaposi Varicelliform Eruption/pathology , Mice , Organophosphonates/administration & dosage
2.
Br J Dermatol ; 170 Suppl 1: 7-11, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24720588

ABSTRACT

Atopic dermatitis (AD) is a common, chronic inflammatory skin disease with a highly variable clinical phenotype and heterogeneous pathophysiology. Its pathogenesis is associated with alterations to both the skin barrier and the immune system, which may in turn be influenced by genetic mutations and the patient's environment. Basic and translational research, as well as clinical trials, have helped broaden our knowledge of the molecular mechanisms underlying the development of AD and to identify potential treatment targets and approaches. These include new ways of reducing transepidermal water loss and the shedding of corneocytes, new ways of interacting with established molecular targets (such as histamine receptors and interleukins and other T-cell cytokines), and the identification of new molecular targets (such as toll-like receptors and tight junction proteins). Well-established treatment options such as emollients, corticosteroids and topical calcineurin inhibitors will clearly continue to have a role in treating AD. Among the new agents that could be joining them in the near future are sphinganin (a precursor of ceramides 1 and 3), cannabinoids, highly targeted monoclonal antibodies and subcutaneous immunotherapy.


Subject(s)
Dermatitis, Atopic/therapy , Adaptive Immunity/physiology , Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Antimicrobial Cationic Peptides/immunology , Cannabinoids/therapeutic use , Dendritic Cells/immunology , Dermatitis, Atopic/immunology , Dermatitis, Atopic/physiopathology , Enzyme Inhibitors/therapeutic use , Epidermis/physiology , Humans , Immunoglobulin E/immunology , Immunotherapy/methods , Kaposi Varicelliform Eruption/prevention & control , Mast Cells/immunology , Receptors, Histamine/immunology , Sphingosine/analogs & derivatives , Sphingosine/therapeutic use , Staphylococcal Skin Infections/prevention & control , Vitamin D/immunology , Water Loss, Insensible/immunology , Water Loss, Insensible/physiology
3.
Clin Infect Dis ; 54(6): 832-40, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22291103

ABSTRACT

Eczema vaccinatum (EV) is a complication of smallpox vaccination that can occur in persons with eczema/atopic dermatitis (AD), in which vaccinia virus disseminates to cause an extensive rash and systemic illness. Because persons with eczema are deferred from vaccination, only a single, accidentally transmitted case of EV has been described in the medical literature since military vaccination was resumed in the United States in 2002. To enhance understanding of EV, we review its history during the era of universal vaccination and discuss its relationship to complications in persons with other diseases or injuries of the skin. We then discuss current concepts of the pathophysiology of AD, noting how defective skin barrier function, epidermal hyperplasia, and abnormal immune responses favor the spread of poxviral infection, and identify a number of unanswered questions about EV. We conclude by considering how its occurrence might be minimized in the event of a return to universal vaccination.


Subject(s)
Dermatitis, Atopic/complications , Eczema/complications , Kaposi Varicelliform Eruption/complications , Kaposi Varicelliform Eruption/virology , Smallpox Vaccine/adverse effects , Animals , Dermatitis, Atopic/physiopathology , Humans , Kaposi Varicelliform Eruption/prevention & control , Skin/physiopathology
6.
Antivir Ther ; 16(1): 67-75, 2011.
Article in English | MEDLINE | ID: mdl-21311110

ABSTRACT

BACKGROUND: Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema). METHODS: Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of human eczema vaccinatum. RESULTS: Using a small animal model of eczema vaccinatum, we demonstrated that both murine and fully human monoclonal antibodies effectively limited eczema vaccinatum disease, foreshortening both the disease kinetics and the severity of the erosive viral skin lesions. CONCLUSIONS: These neutralizing antibodies would likely be effective at reducing or eliminating clinical disease in people with eczema vaccinatum or other severe side effects of the smallpox vaccine.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antibodies, Neutralizing/administration & dosage , Kaposi Varicelliform Eruption/immunology , Kaposi Varicelliform Eruption/prevention & control , Protective Agents/administration & dosage , Smallpox Vaccine/adverse effects , Vaccination/adverse effects , Animals , Antibodies, Monoclonal, Murine-Derived/immunology , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antibodies, Neutralizing/immunology , Antibodies, Neutralizing/therapeutic use , Dermatitis, Atopic/complications , Dermatitis, Atopic/immunology , Disease Models, Animal , Humans , Kaposi Varicelliform Eruption/etiology , Kaposi Varicelliform Eruption/virology , Mice , Mice, Inbred Strains , Protective Agents/therapeutic use , Smallpox/immunology , Smallpox/prevention & control , Smallpox Vaccine/administration & dosage , Vaccinia virus/immunology , Vaccinia virus/pathogenicity
8.
J Immunol ; 172(3): 1763-7, 2004 Feb 01.
Article in English | MEDLINE | ID: mdl-14734759

ABSTRACT

Possible bioterrorism with smallpox has led to the resumption of smallpox (vaccinia virus) immunization. One complication, eczema vaccinatum, occurs primarily in patients with atopic dermatitis (AD). Skin lesions of patients with AD, but not psoriasis, is deficient in the cathelicidin antimicrobial peptide (LL-37) and human beta-defensin-2 (HBD-2). We hypothesized that this defect may explain the susceptibility of patients with AD to eczema vaccinatum. The Wyeth vaccine strain of vaccinia virus was incubated with varying concentrations of human (LL-37) and murine (CRAMP) cathelicidins, human alpha-defensin (HBD-1, HBD-2), and a control peptide. Outcomes included quantification of viral PFU, vaccinia viral gene expression by quantitative real-time RT-PCR, and changes in virion structure by transmission electron microscopy. CRAMP knockout mice and control animals were inoculated by skin pricks with 2 x 10(5) PFU of vaccinia and examined daily for pox development. Physiologic amounts of human and murine cathelicidins (10-50 micro M), but not human defensins, which had antibacterial activity, resulted in the in vitro reduction of vaccinia viral plaque formation (p < 0.0001), vaccinia mRNA expression (p < 0.001), and alteration of vaccinia virion structure. In vivo vaccinia pox formation occurred in four of six CRAMP knockout animals and in only one of 15 control mice (p < 0.01). These data support a role for cathelicidins in the inhibition of orthopox virus (vaccinia) replication both in vitro and in vivo. Susceptibility of patients with AD to eczema vaccinatum may be due to a deficiency of cathelicidin.


Subject(s)
Antimicrobial Cationic Peptides/toxicity , Kaposi Varicelliform Eruption/prevention & control , Keratins/toxicity , Vaccinia virus/growth & development , Amino Acid Sequence , Animals , Antimicrobial Cationic Peptides/administration & dosage , Cathelicidins , Drug Resistance, Microbial , Humans , Kaposi Varicelliform Eruption/genetics , Kaposi Varicelliform Eruption/immunology , Kaposi Varicelliform Eruption/virology , Keratins/administration & dosage , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Microbial Sensitivity Tests , Molecular Sequence Data , Polymerase Chain Reaction , Proteins/genetics , Proteins/physiology , Proteins/toxicity , RNA, Viral/antagonists & inhibitors , RNA, Viral/biosynthesis , Vaccinia/genetics , Vaccinia/immunology , Vaccinia/prevention & control , Vaccinia virus/drug effects , Vaccinia virus/genetics , Virus Replication/genetics
12.
Med J Aust ; 2(16): 620-1, 1976 Oct 16.
Article in English | MEDLINE | ID: mdl-1004311

ABSTRACT

Smallpox has disappeared from all countries except Ethiopia and the possibility of its eradication appears within reach. The need for vaccination of eczema patients against smallpox appears to be ending. Eczema vaccinatum is a rare but sometimes fatal complication of smallpox vaccination in atopic aczema and its incidence is discussed. Precautions in vaccinating atopic eczema patients include suitable treatment of the eczema, injection of vaccinial immunoglobulin and testing the competence of humoral and cellular immunity.


Subject(s)
Eczema/complications , Kaposi Varicelliform Eruption/etiology , Smallpox/prevention & control , Vaccination/adverse effects , Child , Child, Preschool , Humans , Immunoglobulins/therapeutic use , Infant , Kaposi Varicelliform Eruption/epidemiology , Kaposi Varicelliform Eruption/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...